Lisata Therapeutics, a biotech focused on solid tumors, is merging with Marea Therapeutics, a company developing treatments for cardiovascular and endocrine diseases. The all-stock merger, announced alongside a $225 million financing package, will fund the continued development of Marea's two mid-stage drug candidates. The combined company will list on Wall Street under Lisata's name.
This deal marks a fresh start for Lisata after a previous acquisition attempt collapsed, resulting in significant layoffs and a lawsuit. The two companies' pipelines are complementary rather than overlapping, with Lisata bringing its oncology assets and Marea contributing its metabolic and cardiovascular programs. Both sources agree on the core terms and the strategic rationale, though Fierce Biotech emphasizes the troubled history leading to the merger, while BioPharma Dive focuses on the financial backing and pipeline potential.